Amicus Therapeutics
FOLD
FOLD was delisted on the 24th of April, 2026.
287 hedge funds and large institutions have $2.46B invested in Amicus Therapeutics in 2025 Q3 according to their latest regulatory filings, with 51 funds opening new positions, 108 increasing their positions, 93 reducing their positions, and 34 closing their positions.
50% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 34
34% more capital invested
Capital invested by funds: $1.83B → $2.46B (+$629M)
16% more repeat investments, than reductions
Existing positions increased: 108 | Existing positions reduced: 93
6% more funds holding
Funds holding: 272 → 287 (+15)
2% more call options, than puts
Call options by funds: $9M | Put options by funds: $8.8M
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
2.45% less ownership
Funds ownership: 103.75% → 101.3% (-2.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$33.4M |
| 2 |
Millennium Management
New York
|
+$31.2M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$27.6M |
| 4 |
Pictet Asset Management
Carouge,
Switzerland
|
+$20.5M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$16.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$22.5M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
-$21.2M |
| 3 |
D.E. Shaw & Co
New York
|
-$17.7M |
| 4 |
VPC
Vestal Point Capital
New York
|
-$15.3M |
| 5 |
PM
Prosight Management
Dallas,
Texas
|
-$12.6M |
FOLD Hedge Fund Activity: Q3 2025 in Review
287 of the 7,641 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q3 2025, worth a combined $2.46B — up 34% from $1.83B a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new FOLD positions and 34 closed out — a net gain of 17 holders — while 108 added to existing stakes and 93 trimmed.
The largest buyer was Soleus Capital Management, opening a new position worth an estimated $33.4M. The largest seller was Macquarie Group, cutting an estimated $22.5M.
- 287 institutional investors held Amicus Therapeutics (FOLD) as of Q3 2025, up from 272 in Q2 2025.
- Funds reported $2.46B of Amicus Therapeutics stock for Q3 2025, up 34% quarter-over-quarter.
- 51 funds opened new Amicus Therapeutics positions in Q3 2025 and 34 closed out, a net change of +17 holders.
- The largest Amicus Therapeutics buyer in Q3 2025 was Soleus Capital Management, an estimated $33.4M added.
- The largest Amicus Therapeutics seller in Q3 2025 was Macquarie Group, an estimated $22.5M sold.
Based on aggregated 13F filings for Q3 2025.